- Home
- CLDX vs IBRX Comparison
CLDX vs IBRX Comparison
Compare CLDX & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- IBRX
- Stock Information
- Founded
- CLDX 1983
- IBRX 2014
- Country
- CLDX United States
- IBRX United States
- Employees
- CLDX N/A
- IBRX N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLDX Health Care
- IBRX Health Care
- Exchange
- CLDX Nasdaq
- IBRX Nasdaq
- Market Cap
- CLDX 1.7B
- IBRX 1.9B
- IPO Year
- CLDX 2008
- IBRX N/A
- Fundamental
- Price
- CLDX $22.46
- IBRX $3.42
- Analyst Decision
- CLDX Buy
- IBRX Strong Buy
- Analyst Count
- CLDX 8
- IBRX 3
- Target Price
- CLDX $61.86
- IBRX $13.58
- AVG Volume (30 Days)
- CLDX 774.1K
- IBRX 6.0M
- Earning Date
- CLDX 03-04-2025
- IBRX 03-18-2025
- Dividend Yield
- CLDX N/A
- IBRX N/A
- EPS Growth
- CLDX N/A
- IBRX N/A
- EPS
- CLDX N/A
- IBRX N/A
- Revenue
- CLDX $9,976,000.00
- IBRX $7,332,000.00
- Revenue This Year
- CLDX N/A
- IBRX $2,359.81
- Revenue Next Year
- CLDX N/A
- IBRX $808.10
- P/E Ratio
- CLDX N/A
- IBRX N/A
- Revenue Growth
- CLDX 128.55
- IBRX 1218.71
- 52 Week Low
- CLDX $20.91
- IBRX $2.28
- 52 Week High
- CLDX $53.18
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- CLDX 42.55
- IBRX 52.26
- Support Level
- CLDX $22.38
- IBRX $3.35
- Resistance Level
- CLDX $23.69
- IBRX $4.27
- Average True Range (ATR)
- CLDX 1.07
- IBRX 0.31
- MACD
- CLDX 0.03
- IBRX 0.04
- Stochastic Oscillator
- CLDX 44.67
- IBRX 29.17
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.